FDA grants priority review to Biologics License Application for loncastuximab tesirine for treatment of relapsed/refractory diffuse large B-cell lymphoma

Loncastuximab tesirine, an antibody drug conjugate, consists of a humanized monoclonal antibody designed to target human CD19, a treatment target for B-cell malignancies. The drug, once bound to a CD19-expressing cell, is internalized by the cell.

Source:

Biospace Inc.